Thus, olanzapine-induced disturbance of intracellular trafficking and secretion of apoA5 potentially contributes to the development of NAFLD in schizophrenia patients, which had been verified in olanzapine-treated mice and supported by other studies (Schaap et al., 2004; Grosskopf et al., 2005; Li et al., 2021). Here, APOA5 is linked to metabolic dysfunction-associated steatotic liver disease.